Tag: Amyotrophic lateral sclerosis

  • The ALS pen – digital precision for ALS research

    The ALS pen – digital precision for ALS research

    —

    by

    admin
    in , ,

    With the ALS pen, we are presenting a new project for the structured and quantifiable recording of hand motor skills in the course of amyotrophic lateral sclerosis (ALS) for the first time. Our aim is to record motor changes in the hand of people with ALS in a more differentiated and standardized way. To this…

  • ALS network symposium with APST in Berlin on April 16, 2026

    ALS network symposium with APST in Berlin on April 16, 2026

    —

    by

    admin
    in ,

    The ALS Network Symposium will take place in Berlin from Wednesday, April 15 to Friday, April 17. Traditionally, the symposium begins on Wednesday evening with an informal get-together. On Thursday, the following topics are planned by APST and Charité – Universitätsmedizin Berlin: – the ALS phenotype biomarker registry with a focus on ALS-OPM classification, NfL…

  • DMC in ALS

    DMC in ALS

    —

    by

    admin
    in ,

    During the course of their disease, around 90% of patients with ALS develop speech or swallowing difficulties – so-called bulbar symptoms. Around a third of all patients already show bulbar symptoms at the onset of ALS. Dextromethorphan/quinidine (DMC) has established itself as an off-label treatment option to alleviate these symptoms in ALS. In a patient…

  • Together since 2011 – 15 years of APST

    Together since 2011 – 15 years of APST

    —

    by

    admin
    in ,

    2026 is a special year for us: APST is celebrating its 15th anniversary. Since our founding, we have stood for reliable support, dedicated research, and digital services for people with ALS, SMA, and other motor neuron diseases. Thank you for your trust, your loyalty, and the many shared experiences over the past years. We look…

  • The ALS app at the international ALS symposium in San Diego

    The ALS app at the international ALS symposium in San Diego

    —

    by

    admin
    in , ,

    On December 4, 2025, the ALS app will be presented at the“ALS App Europe Initiative Meeting” at the International Symposium on ALS/MND in San Diego (USA). The meeting brings together European and American ALS centers, researchers and patient initiatives. You can find out more about the program here: https://symposium.mndassociation.org/programme/satellite-meetings/ The “ALS App Europe Initiative” meeting…

  • Which ALS outpatient clinics use the OPM classification?

    Which ALS outpatient clinics use the OPM classification?

    —

    by

    admin
    in ,

    Following our last newsletter on the introduction of the OPM classification in the ALS app, we have received numerous queries: Which ALS outpatient clinics in Germany already use the OPM classification as part of the “NfL study in ALS”? We are pleased to be able to provide you with a transparent overview. ALS outpatient clinics…

  • Submit your e-prescription in the ALS app at your ALS pharmacy and continue to support ALS research

    Submit your e-prescription in the ALS app at your ALS pharmacy and continue to support ALS research

    —

    by

    admin
    in ,

    You can now submit your e-prescription with your health card via the ALS app at your specialist ALS pharmacy! You can also continue to be supplied via your ALS pharmacy with the e-prescription and take part in ALS research. Have four things ready: Electronic health card. You will find the 6-digit CAN number (“Card Access…

  • The new ALS-OPM classification is now in the ALS app.

    The new ALS-OPM classification is now in the ALS app.

    —

    by

    admin
    in , ,

    We are pleased to introduce an important new feature in the ALS app today: The new OPM classification is now live! The OPM classification has been available in the current app version 5.10.4 for iOS (Apple) and Android (Google) since yesterday. What does the OPM classification mean? The phenotype of ALS – i.e. the individual…

  • Patient survey on THC:CBD in people with ALS

    Patient survey on THC:CBD in people with ALS

    —

    by

    admin
    in , ,

    The THC:CBD patient survey is a systematic survey of 130 patients with amyotrophic lateral sclerosis (ALS), in which important findings on experience and satisfaction with treatment with cannabis-containing medicines containing tetrahydrocannabinol (THC) and cannabidiol (CBD) are obtained. Cannabis-containing treatment for ALS Medicines containing cannabis are used for severe illnesses when conventional medicines are not sufficiently…

  • New medication module in the outpatient partner care portal

    New medication module in the outpatient partner care portal

    —

    by

    admin
    in ,

    We are pleased to inform you that we have completely revised our medication module. With the new version, we want to make the medication supply processes more transparent, efficient and clearer. It went live in the Ambulanzpartner care portal on September 22, 2025. The old and new medication modules will be available in parallel in…